Literature DB >> 19633798

[Churg-Strauss syndrome: outcome and long-term follow-up of 38 patients from a single Italian centre].

C Baldini1, A Della Rossa, S Grossi, E Catarsi, R Talarico, A d'Ascanio, M Mosca, R Neri, A Tavoni, S Bombardieri.   

Abstract

OBJECTIVE: This study was aimed at verifying any potential correlation between anti-myeloperoxidase antineutrophil cytoplasmic antibodies (ANCA-MPO) and clinical features and outcome indices in Churg-Strauss Syndrome (CSS).
METHODS: Thirty-eight Churg-Strauss syndrome patients were selected from the medical records of all vasculitis patients attending the Rheumatology and Immunology Unit at the Department of Internal Medicine of the University of Pisa in the decades between 1989 and 2008. Data were analysed retrospectively. Statistical analyses of the results were carried out using the Mann-Whitney test to determine the correlations between the clinical and serological parameters. Qualitative variables were compared using contingency table analysis and Fisher's exact test.
RESULTS: ANCA-MPO were detected in15/38 (39%) patients. Positive ANCA status was associated with peripheral neuropathy (p=0.0006), whereas negative ANCA status was associated with lung involvement (p=0.002). Relapses were strongly associated with positive ANCA status (p=0.01) and with an increase in- or a reappearance of ANCA-MPO levels (p=0.006). Finally, ANCA-MPO were significantly associated with neurological damage (p=0.003).
CONCLUSIONS: The presence or absence of ANCA-MPO identify different clinical subsets in CSS. Overall, ANCA-MPO appears as a useful tool in the monitoring of CSS and in particular a good predictor of CSS relapses.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19633798     DOI: 10.4081/reumatismo.2009.118

Source DB:  PubMed          Journal:  Reumatismo        ISSN: 0048-7449


  5 in total

Review 1.  Updates in ANCA-associated vasculitis.

Authors:  Christian Pagnoux
Journal:  Eur J Rheumatol       Date:  2016-01-29

Review 2.  Cutaneous manifestations of Churg-Strauss syndrome: report of two cases and review of the literature.

Authors:  Laura Bosco; Anna Peroni; Donatella Schena; Chiara Colato; Giampiero Girolomoni
Journal:  Clin Rheumatol       Date:  2010-10-15       Impact factor: 2.980

3.  Clinical Manifestations and Long-Term Outcomes of Eosinophilic Granulomatosis With Polyangiitis in North America.

Authors:  Irena Doubelt; David Cuthbertson; Simon Carette; Sharon A Chung; Lindsy J Forbess; Nader A Khalidi; Curry L Koening; Carol Langford; Carol A McAlear; Larry W Moreland; Paul A Monach; Philip Seo; Ulrich Specks; Robert F Spiera; Jason M Springer; Antoine G Sreih; Kenneth J Warrington; Peter A Merkel; Christian Pagnoux
Journal:  ACR Open Rheumatol       Date:  2021-05-25

4.  An aggressive and lethal course of Churg-Strauss syndrome with alveolar hemorrhage, intestinal perforation, cardiac failure and peripheral neuropathy.

Authors:  Aydin Çiledağ; Hülya Deniz; Serpil Eledağ; Canan Özkal; Nurşen Düzgün; Selim Erekul; Demet Karnak
Journal:  Rheumatol Int       Date:  2009-12-19       Impact factor: 3.580

5.  Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis.

Authors:  Vítor Teixeira; Aladdin J Mohammad; Rachel B Jones; Rona Smith; David Jayne
Journal:  RMD Open       Date:  2019-06-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.